Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Low levels of invasive fungal coinfections seen in COVID-19 patients compared to bacterial infections
Key clinical point: The low levels of invasive fungal infections (less than 1%) were attributed to line-related infections.
Major finding: Bacterial isolates were identified in 3.2% of patients during the early admission period rising to 6.1% during hospitalization.
Study details: 836 patients with confirmed SARS-CoV-2 were assessed.
Disclosures: The study was unsponsored. The authors reported receiving funding from a variety of pharmaceutical companies.
Citation:
Hughes S et al. Clinical Microbiology and Infection. 2020; doi.org/10.1016/j.cmi.2020.06.025.